The Prognostic Significance of the Tumor-Infiltrating FoxP3-Positive Regulatory T Cells in Gastric Carcinoma
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background : Regulatory T cells (Tregs) are known to be key regulators of immune responses in patients with autoimmune disease and infection and also for attenuating antitumor immunity by the host. It has been reported that high numbers of tumor-infiltrating Tregs might be associated with poor clinical outcomes for several malignant tumors. Therefore, this study aimed to examine the impact of tumor-infiltrating Tregs on the prognosis of gastric carcinoma patients. Methods : The immunohistochemical staining for anti-fork head Box P3 (FoxP3) antibody was performed by using a 3 mm core from the tumor specimens of each of the 173 gastric cancer patients for constructing a tissue microarray. FoxP3-positive Tregs were quantified by calculating the numbers of positive cells per 5 high-power fields on light microscopy. Thereafter, the 173 patients were subdivided into the low Tregs group (≤3/5 high power fields [HPF], n = 41) and the high Tregs group (> 3/5 HPF, n = 132). Results : The high Tregs group was significantly associated with a higher stage, more invasion depth and lymph node metastasis (p = 0.009, p = 0.036, p = 0.006, respectively). The high Tregs group showed significantly poorer overall survival and event-free survival (p = 0.004, p = 0.017, respectively) on the univariate analysis. The Tregs group and the tumor, node and metastasis stage were also independent prognostic factors that were significantly associated with overall survival (p = 0.025, p < 0.001, respectively) by multivariate analysis. Conclusions : Our results indicated that a high number of tumor-infiltrating FoxP3-positive Tregs could be an indicator of poor long term survival for gastric carcinoma patients.
Abstract
Background : Regulatory T cells (Tregs) are known to be key regulators of immune responses in patients with autoimmune disease and infection and also for attenuating antitumor immunity by the host. It has been reported that high numbers of tumor-infiltrating Tregs might be associated with poor clinical outcomes for several malignant tumors. Therefore, this study aimed to examine the impact of tumor-infiltrating Tregs on the prognosis of gastric carcinoma patients. Methods : The immunohistochemical staining for anti-fork head Box P3 (FoxP3) antibody was performed by using a 3 mm core from the tumor specimens of each of the 173 gastric cancer patients for constructing a tissue microarray. FoxP3-positive Tregs were quantified by calculating the numbers of positive cells per 5 high-power fields on light microscopy. Thereafter, the 173 patients were subdivided into the low Tregs group (≤3/5 high power fields [HPF], n = 41) and the high Tregs group (> 3/5 HPF, n = 132). Results : The high Tregs group was significantly associated with a higher stage, more invasion depth and lymph node metastasis (p = 0.009, p = 0.036, p = 0.006, respectively). The high Tregs group showed significantly poorer overall survival and event-free survival (p = 0.004, p = 0.017, respectively) on the univariate analysis. The Tregs group and the tumor, node and metastasis stage were also independent prognostic factors that were significantly associated with overall survival (p = 0.025, p < 0.001, respectively) by multivariate analysis. Conclusions : Our results indicated that a high number of tumor-infiltrating FoxP3-positive Tregs could be an indicator of poor long term survival for gastric carcinoma patients.
참고문헌 (30)
- Sakaguchi S, "Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains(CD25):breakdown of a single mechanism of self-tolerance causes various autoimmune diseases", J Immunol, 155, pp.1151~1164 (1995)
- Lepault F, "Characterization of peripheral regulatory CD4+ T cells that prevent diabetes onset in nonobese diabetic mice", J Immunol, 164, pp.240~247 (2000)
- Read S, "CD38+ CD45RB(low)CD4+ T cells:a population of T cells with immune regulatory activities in vitro", Eur J Immunol, 28, pp.3435~3447 (1998)
- Hori S, "Control of regulatory T cell development by the transcription factor Foxp3", Science, 299, pp.1057~1061 (2003)
- Wolf AM, "Increase of regulatory T cells in the peripheral blood of cancer patients", Clin Cancer Res, 9, pp.606~612 (2003)
- Bates GJ, "Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse", J Clin Oncol, 24, pp.5373~5380 (2006)
- Petersen RP, "Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients", Cancer, 107, pp.2866~2872 (2006)
- Wolf D, "The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is asso-ciated with poor prognosis in ovarian cancer", Clin Cancer Res, 11, pp.8326~8331 (2005)
- Sasaki A, "Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma", Eur J Surg Oncol, 34, pp.173~179 (2008)
- Crew KD, "Epidemiology of gastric cancer", World J Gastroenterol, 12, pp.354~362 (2006)
- Hamilton SR, "World Health Organization Classification of Tumours: pathology and genetics of tumours of the digestive system" (2000), IARC Press
- Perrone G, "Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer", Eur J Cancer, 44, pp.1875~1882 (2008)
- Kono K, "CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers", Cancer Immunol Immunother, 55, pp.1064~71 (2006)
- Ichihara F, "Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers", Clin Cancer Res, 9, pp.4404~4408 (2003)
- Sasada T, "CD4+CD-25+ regulatory T cells in patients with gastrointestinal malignancies:possible involvement of regulatory T cells in disease progression", Cancer, 98, pp.1089~1099 (2003)
- Mizukami Y, "Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer", Br J Cancer, 98, pp.148~153 (2008)
- Zou W, "Immunosuppressive networks in the tumour environment and their therapeutic relevance", Nat Rev Cancer, 5, pp.263~274 (2005)
- Ghiringhelli F, "Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation", J Exp Med, 202, pp.919~929 (2005)
- Sakaguchi S, "Regulatory T cells and immune tolerance", Cell, 133, pp.775~787 (2008)
- Onishi Y, "Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation", Proc Natl Acad Sci U S A, 105, pp.10113~10118 (2008)
- Zhao DM, "Activated CD-4+CD25+ T cells selectively kill B lymphocytes", Blood, 107, pp.3925~3932 (2006)
- Donovan D, "TGF beta-1 regulation of VEGF production by breast cancer cells", Ann Surg Oncol, 4, pp.621~627 (1997)
- Li B, "Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy", Clin Cancer Res, 12, pp.6808~6816 (2006)
- Zhang B, "Expression of vascular endothelial growth factors-C and-D correlate with evidence of lymphangiogenesis and angiogenesis in pancreatic adenocarcinoma", Cancer Detect Prev, 31, pp.436~442 (2007)
- Gupta S, "Intratumoral FOXP3 expression in infiltrating breast carcinoma:its association with clinicopathologic parameters and angiogenesis", Acta Oncol, 46, pp.792~797 (2007)
- Kawaida H, "Distribution of CD4+CD25 high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer", J Surg Res, 124, pp.151~157 (2005)
- Viguier M, "Foxp3 expressing CD4+CD25(high)regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells", J Immunol, 173, pp.1444~1453 (2004)
- Onizuka S, "Tumor rejection by in vivo administration of anti-CD25(interleukin-2 receptor alpha)monoclonal antibody", Cancer Res, 59, pp.3128~3133 (1999)
- Dannull J, "Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells", J Clin Invest, 115, pp.3623~3633 (2005)
- Lutsiak ME, "Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide", Blood, 105, pp.2862~2868 (2005)